読み込み中
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
前日終値
$16.46
−$0.27 · -1.61%
時間外
$16.21
−$0.25 · -1.52%
10月12日 19:58 ET
日中の時刻はETです。市場データは遅延する場合があります。
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
日中レンジ
現在 $16.46
52週レンジ
現在 $16.46
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
36
割高
センチメント
58
まちまち
リスク
46
やや高いリスク
モメンタム
67
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
日中レンジ
現在 $16.46
52週レンジ
現在 $16.46
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1.53億 USD | 7900.4万 USD | 6488.4万 USD | 3043.3万 USD | 643.4万 USD |
| 販売・一般管理 | 2418.3万 USD | 1530.4万 USD | 970.6万 USD | 647.3万 USD | 226.2万 USD |
| 営業費用 | 1.78億 USD | 9430.8万 USD | 7459万 USD | 3690.6万 USD | 869.6万 USD |
| 受取利息 | 1122.6万 USD | 1382万 USD | 525.7万 USD | — | — |
| 減価償却費と償却費 | — | — | — | 3690.6万 USD | — |
| 営業利益 | −1.78億 USD | −9430.8万 USD | −7459万 USD | −3690.6万 USD | −869.6万 USD |
| 純利益 | −1.66億 USD | −8048.8万 USD | −6933.3万 USD | −3690.6万 USD | −5160.6万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI4022.99万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM1654.36万0.02%787.4億 USD0.19%$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1513.04万0.15%103.03億 USD0.35%$151.4-1.54%
Vanguard Extended Market ETFVXF1207.01万0.01%954億 USD0.05%$233.52-0.63%
Vanguard Russell 2000 ETFVTWO654.45万0.04%180億 USD0.06%$112.27-0.35%
iShares Russell 2000 Growth ETFIWO582.73万0.04%139.17億 USD0.24%$353.71-0.86%
iShares Biotechnology ETFIBB450.07万0.04%108.2億 USD0.44%$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA362万0.02%218.24億 USD0.03%$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
